← Leaderboards
Ian S Zagon
Pennsylvania State Univ Hershey Med Ctr
$4,047,867
Attributed
$4,047,867
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $390.6K · FY2005–21$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,047,867 · 6
By mechanism
R01$1,720,592 · 2
R33$959,934 · 1
R21$953,536 · 2
R03$413,805 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Opioid Receptor”
- Charles P France · University Of Texas Hlth Science Center$30,774,689
- Jeffrey Reich · Sparian Biosciences, Inc.$28,894,251
- Kurt Francis Hauser · University Of Kentucky$25,730,611
- Xinhua Li · Nano Terra, Inc.$21,217,757
- Sandra D. Comer · New York State Psychiatric Institute$20,243,615
- Mark E. Von Zastrow · University Of California, San Francisco$19,881,705
Research focus
Opioid ReceptorWound HealingCorneaNaltrexoneReceptor ExpressionCorneal EpitheliumStreptozocinOryctolagus CuniculusTopical ApplicationRattusDiabetes MellitusLaboratory RatCorneal AbrasionEpithelialAnimalsDefectComplications Of Diabetes MellitusBlindnessDiabeticEnkephalinsInsulinPreventKeratopathyScientist
Grant awards (15)
OGF-OGFr Axis Modulation to Prevent Diabetic Ocular Surface Complications.$370,544
R01 · FY2021 · EY · contact PI
OGF-OGFr Axis Modulation to Prevent Diabetic Ocular Surface Complications.$382,048
R01 · FY2020 · EY · contact PI
OGF-OGFr Axis Modulation to Prevent Diabetic Ocular Surface Complications.$382,088
R01 · FY2019 · EY · contact PI
OGF-OGFr Axis Modulation to Prevent Diabetic Ocular Surface Complications.$382,128
R01 · FY2018 · EY · contact PI
Naltrexone as a Novel Treatment for Diabetic Keratopathy$197,056
R33 · FY2010 · EY · contact PI
Naltrexone as a Novel Treatment for Diabetic Keratopathy$372,289
R33 · FY2007 · EY · contact PI
Naltrexone as a Novel Treatment for Diabetic Keratopathy$390,589
R33 · FY2006 · EY · contact PI
Naltrexone as a Novel Treatment for Diabetic Keratopathy$360,826
R21 · FY2005 · EY
Naltrexone as a Novel Treatment for Diabetic Keratopathy$358,121
R21 · FY2004 · EY
Gene Gun Technology, Opioids, and Corneal Diseases$140,500
R03 · FY2003 · EY
Gene Gun Technology, Opioids, and Corneal Diseases$140,500
R03 · FY2002 · EY
Gene Gun Technology, Opioids, and Corneal Diseases$132,805
R03 · FY2001 · EY
ENDOGENOUS OPIOID MODULATION OF HUMAN PANCREATIC CANCER$203,784
R01 · FY2000 · CA
REGULATION OF CORNEAL WOUND HEALING IN TYPE I DIABETES$195,765
R21 · FY2000 · EY
REGULATION OF CORNEAL WOUND HEALING IN TYPE I DIABETES$38,824
R21 · FY2000 · EY